By Kamal Choudhury and Christy Santhosh
(Reuters) -The U.S. Food and Drug Administration on Thursday approved Kura Oncology and Japanese partner Kyowa Kirin's once-daily pill, Komzifti, to treat a rare form of blood cancer that has returned or stopped responding to treatment.
The drug is approved for acute myeloid leukemia patients with an NPM1 mutation, a genetic change found in about 30% of cases.
Acute myeloid leukemia is an aggressive cancer of the blood and bone marrow.
Kura said the drug will be available within the next few business days at a price of $48,500 for a one-month supply.
With the approval, Kura's drug now competes with Syndax Pharmaceuticals' Revuforj, which was approved for the same indication by the FDA last month.
Komzifti’s approval comes with a boxed warning for differentiation syndrome and an additional warning for QTc interval prolongation, a delay in the heart’s electrical recovery after a beat, and potential harm to unborn babies.
A boxed warning is the U.S. Food and Drug Administration’s strongest alert for serious or life-threatening risks and appears prominently on a drug’s label to warn doctors and patients.
Revuforj carries a boxed warning for QTc interval prolongation, giving Kura “a significant competitive advantage,” according to Wedbush analysts.
Kura's Chief Medical Officer Mollie Leoni said the risk of QTc prolongation with Komzifti is low, adding it is “extraordinarily unlikely” to lead to a boxed warning.
The company said it is in dialogue with the FDA about potential steps post-approval that could help refine the labeling.
Under the terms of its collaboration with Kyowa, Kura is responsible for manufacturing Komzifti and will lead commercialization in the United States, while Kyowa handles commercial strategy and development outside the U.S.
Analysts, on average, expect Komzifti to have annual sales of $1.32 billion by 2031, according to LSEG data.
(Reporting by Kamal Choudhury and Christy Santhosh in Bengaluru; Editing by Shailesh Kuber and Tasim Zahid)
LATEST POSTS
- 1
Robyn returns to music with 'Dopamine,' her 1st single in 7 years: 'Came to save music once again' - 27 Moves toward a Sound and Dynamic Way of life
- 3East Germany Somehow Built a Real Sports Car and It Was Wild
- 4Track down the Ideal Weight reduction Methodology for Your Way of life
- 5Former Israeli judge does not expect Netanyahu to be pardoned
- Remain Fit: Powerful Wellness and Work-out Schedules for a Better You
- Real time features for Films and Programs
- ‘Nahariya get ready’: Banner displaying Hezbollah threat mounted in Tehran’s Palestine Square
- Health officials report 14 Legionnaires' disease cases in Florida, gym connection suspected
- Death toll from floods in Afghanistan rises to 61
- Ukraine demands army of 800,000 under peace plan
- The race to mine the moon is on – and it urgently needs some clear international rules
- Bolsonaro says hallucinatory effects of meds made him tamper with ankle tag
- Video Conferencing Instruments for Virtual Gatherings
